Top-Rated StocksTop-RatedNASDAQ:RARE Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis $58.75 -0.03 (-0.05%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ultragenyx Pharmaceutical alerts: Email Address About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RARE alerts:Sign Up Key Stats Today's Range$57.91▼$59.0950-Day Range$42.55▼$59.3652-Week Range$31.52▼$60.37Volume841,049 shsAverage Volume792,200 shsMarket Capitalization$5.41 billionP/E RatioN/ADividend YieldN/APrice Target$87.43Consensus RatingModerate Buy Company OverviewUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Read More… Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on retiring any time soon... Every retirement dollar you have invested in paper assets will only continue to drop in value. We just released a Free Guide that reveals all the details.Click here to get the free Gold Guide now. Ultragenyx Pharmaceutical Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 95th PercentileUltragenyx Pharmaceutical scored higher than 95% of companies evaluated by MarketBeat, and ranked 58th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageUltragenyx Pharmaceutical has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ultragenyx Pharmaceutical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($6.24) to ($5.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -7.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -7.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUltragenyx Pharmaceutical has a P/B Ratio of 17.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ultragenyx Pharmaceutical's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.81% of the outstanding shares of Ultragenyx Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently decreased by 8.83%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. Sustainability and ESG3.8 / 5Environmental Score-2.28 Percentage of Shares Shorted3.81% of the outstanding shares of Ultragenyx Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently decreased by 8.83%, indicating that investor sentiment is improving significantly. News and Social Media1.7 / 5News Sentiment0.07 News SentimentUltragenyx Pharmaceutical has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Ultragenyx Pharmaceutical this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for RARE on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,149,446.00 in company stock.Percentage Held by InsidersOnly 5.80% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ultragenyx Pharmaceutical's insider trading history. Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Stock News HeadlinesUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells $1,117,000.00 in StockSeptember 6, 2024 | insidertrades.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 18 at 5:00 PM | globenewswire.comTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on retiring any time soon... Every retirement dollar you have invested in paper assets will only continue to drop in value. We just released a Free Guide that reveals all the details.September 20, 2024 | Gold Safe Exchange (Ad)Ultragenyx Pharmaceutical (RARE) Gets a Buy from Bank of America SecuritiesSeptember 17 at 9:46 AM | markets.businessinsider.comUltragenyx Pharmaceutical (NASDAQ:RARE) Given "Overweight" Rating at Cantor FitzgeraldSeptember 17 at 5:25 AM | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Sets New 12-Month High at $58.88September 15, 2024 | americanbankingnews.com0LIF.IL,0P0001H7PQ,91 (0LIF.IL)September 9, 2024 | nz.finance.yahoo.comStifel Nicolaus Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)September 6, 2024 | markets.businessinsider.comSee More Headlines RARE Stock Analysis - Frequently Asked Questions How have RARE shares performed this year? Ultragenyx Pharmaceutical's stock was trading at $47.82 at the beginning of 2024. Since then, RARE stock has increased by 22.9% and is now trading at $58.75. View the best growth stocks for 2024 here. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its quarterly earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.64) by $0.12. The firm's quarterly revenue was up 35.7% compared to the same quarter last year. Who are Ultragenyx Pharmaceutical's major shareholders? Top institutional investors of Ultragenyx Pharmaceutical include Clearbridge Investments LLC (2.83%), Federated Hermes Inc. (2.53%), Millennium Management LLC (2.01%) and Marshall Wace LLP (1.23%). Insiders that own company stock include Emil D Kakkis, Thomas Richard Kassberg, John Richard Pinion, Dennis Karl Huang, Mardi Dier, Karah Herdman Parschauer, Erik Harris, Eric Crombez, Camille L Bedrosian, Theodore Alan Huizenga, Matthew K Fust and Corazon (Corsee) D Sanders. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Micron Technology (MU). Company Calendar Last Earnings8/01/2024Today9/20/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RARE CUSIPN/A CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,276Year Founded2010Price Target and Rating Average Stock Price Target$87.43 High Stock Price Target$130.00 Low Stock Price Target$46.00 Potential Upside/Downside+48.8%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($8.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-606,640,000.00 Net Margins-121.57% Pretax Margin-121.93% Return on Equity-266.02% Return on Assets-41.39% Debt Debt-to-Equity RatioN/A Current Ratio3.54 Quick Ratio3.39 Sales & Book Value Annual Sales$434.25 million Price / Sales12.47 Cash FlowN/A Price / Cash FlowN/A Book Value$3.35 per share Price / Book17.54Miscellaneous Outstanding Shares92,170,000Free Float78,311,000Market Cap$5.41 billion OptionableOptionable Beta0.56 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RARE) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.